Spruce Biosciences (SPRB) Stock Overview
A biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
SPRB Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Spruce Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$85.74 |
| 52 Week High | US$240.00 |
| 52 Week Low | US$4.28 |
| Beta | 3.51 |
| 1 Month Change | -14.26% |
| 3 Month Change | 783.92% |
| 1 Year Change | 161.30% |
| 3 Year Change | 4.17% |
| 5 Year Change | -95.30% |
| Change since IPO | -93.28% |
Recent News & Updates
Shareholder Returns
| SPRB | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 8.9% | 1.1% | 1.3% |
| 1Y | 161.3% | 26.4% | 15.8% |
Return vs Industry: SPRB exceeded the US Biotechs industry which returned 26.4% over the past year.
Return vs Market: SPRB exceeded the US Market which returned 15.8% over the past year.
Price Volatility
| SPRB volatility | |
|---|---|
| SPRB Average Weekly Movement | 388.9% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: SPRB's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: SPRB's weekly volatility has increased from 197% to 389% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 9 | Javier Szwarcberg | sprucebio.com |
Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company develops TA-ERT, a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase, which is an enzyme replacement therapy for patients with Sanfilippo Syndrome Type B. It also develops Tildacerfont for treating a highly debilitating mental disorder characterized by depressed mood with cognitive-affective and somatic changes, including anhedonia, weight alterations, and altered sleeping patterns. In addition, the company develops SPR202 for the treatment of Congenital Adrenal Hyperplasia (CAH), a chronic and potentially life-threatening rare disease with no cure, and SPR204, a monoclonal antibody antagonist for Post-Bariatric Hypoglycemia.
Spruce Biosciences, Inc. Fundamentals Summary
| SPRB fundamental statistics | |
|---|---|
| Market cap | US$91.77m |
| Earnings (TTM) | -US$47.88m |
| Revenue (TTM) | US$697.00k |
Is SPRB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SPRB income statement (TTM) | |
|---|---|
| Revenue | US$697.00k |
| Cost of Revenue | US$36.88m |
| Gross Profit | -US$36.18m |
| Other Expenses | US$11.70m |
| Earnings | -US$47.88m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -44.73 |
| Gross Margin | -5,190.53% |
| Net Profit Margin | -6,869.30% |
| Debt/Equity Ratio | 10.0% |
How did SPRB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/28 18:50 |
| End of Day Share Price | 2025/12/26 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Spruce Biosciences, Inc. is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Aydin Huseynov | Benchmark Company |
| Jonathan Wolleben | Citizens JMP Securities, LLC |
| Raghuram Selvaraju | H.C. Wainwright & Co. |